Re: WowSounds like they are trying to combine the ADC targeting with the immunotherapy approach to tumor suppresion. Here's some comps, it's taken them $80mil over 5 years to get to the end of the Phase 1....! And, here's the confiming "supportive" data from the Phase 1:
"We have seen clinical activity in the form of stable disease, reductions in tumor volume including a confirmed partial response, and increases in pharmacodynamic markers that we believe are consistent with our proposed mechanism of action."
Notice the singular use "...a confirmed partial response..." That's all they showed to support the $230mil raise. Guess stability, a tad of tumor reduction, and readings that are consistent with proposed MOA are all a drug needs to show in the early stages.